Skip NavigationSkip to Content
Return Return to Search Results

The combination of gemcitabine and docetaxel arrests a doxorubicin-resistant dedifferentiated liposarcoma in a patient-derived orthotopic xenograft model

  1. Author:
    Miyake, Kentaro
    Higuchi, Takashi
    Oshiro, Hiromichi
    Zhang, Zhiying
    Sugisawa, Norihiko
    Park, Jun Ho
    Razmjooei, Sahar
    Katsuya, Yuki
    Barangi, Maryam
    Li, Yunfeng
    Nelson, Scott D
    Murakami, Takashi
    Homma, Yuki
    Hiroshima, Yukihiko
    Matsuyama, Ryusei
    Bouvet, Michael
    Chawla, Sant P
    Singh,Shree Ram
    Endo, Itaru
    Hoffman, Robert M

  2. Author Address

    AntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA; Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan., AntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA., Dept. of Pathology, University of California, Los Angeles, CA, USA., Sarcoma Oncology Center, Santa Monica, CA, USA., Basic Research Laboratory, National Cancer Institute, Frederick, MD, USA. Electronic address: singhshr@mail.nih.gov., Department of Gastroenterological Surgery, Yokohama City University Graduate School of Medicine, Yokohama, Japan. Electronic address: endoit@med.yokohama-cu.ac.jp., AntiCancer Inc., San Diego, CA, USA; Department of Surgery, University of California, San Diego, CA, USA. Electronic address: all@anticancer.com.,
    1. Year: 2019
    2. Date: SEP
    3. Epub Date: 2019 06 11
  2. Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
    1. 117
    2. Pages: 109093
  4. Type of Article: Article
  5. Article Number: UNSP 109093
  6. ISSN: 0753-3322
  1. Abstract:

    Liposarcoma (LS) is a chemotherapy-resistant disease. The aim of the present study was to find precise therapy for a recurrent dedifferentiated liposarcoma (DDLS) in a patient-derived orthotopic xenograft (PDOX) model. The DDLS PDOX models were established orthotopically in the right inguinal area of nude mice. The DDLS PDOX models were randomized into five groups: untreated; doxorubicin (DOX); gemcitabine (GEM) combined with docetaxel (DOC); pazopanib (PAZ); and yondelis (YON). On day 15, all mice were sacrificed. Measurement of tumor volume and body weight were done two times a week. The DDLS PDOX was resistant to DOX (P?>?0.184). YON suppressed tumor growth significantly compared to control group (P?< ?0.027). However, only GEM combined with DOC arrested the tumor growth (P?< ?0.001). These findings suggest that GEM combined with DOC has clinical potential for this and possibly other DDLS patients. Copyright © 2019 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1016/j.biopha.2019.109093
  3. PMID: 31200257
  4. View record in Web of Science®
  5. WOS: 000477804500111
  6. PII : S0753-3322(19)32117-1

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel